Who invested in Rhythm Pharmaceuticals

10 rounds we have observed, with the 9 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$311Mraised across 10 rounds since 2010, from 10 sources

$21MSeries A$19MSeries A$9.5MVenture$25MSeries B$8.0MSeries B$11MSeries B$1.4MGrant$40MSeries A$1.0MGrant$175MRound

Latest round: Round, $175MJul 2025
Step-upi: 175×
Investors: 9

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

20102012201420162018202020222024

$21MSeries A$19MSeries A$9.5MVenture$25MSeries B$40MSeries A$1.0MGrant$175MRound

First round: Series A, $21M
Biggest round: $175M
Usual gap between rounds: 8 months

The rounds

Jul 2025
Round$175M2 returning
- New Enterprise Associates
- OrbiMed
Source recorded
Sept 2015
Grant$1.0M
No investor was named in the report.
From a historical funding recordSEC filing: $40M sold, first sale Aug 2015
Aug 2015
Series A$40M3 new5 returning
From a historical funding recordSEC filing: $40M sold, first sale Aug 2015
Sept 2013
Grant$1.4M1 new
- Michael J. Fox Foundation
Reported by bizjournals.com
Jul 2013
Series B$11M
No investor was named in the report.
Reported by biospace.com
Nov 2012
Series B$8.0M1 new4 returning
Reported by pehub.comSEC filing: $23M sold, first sale May 2012
Jun 2012
Series B$25M2 new2 returning
Reported by rhythmtx.comSEC filing: $9.5M sold, first sale May 2012
Jun 2012
Venture$9.5M
No investor was named in the report.
Reported by masshightech.comSEC filing: $9.5M sold, first sale May 2012
Sept 2010
Series A$19M
No investor was named in the report.
Reported by genengnews.comSEC filing: $18M sold, first sale Mar 2010
Mar 2010
Series A$21M2 new
- New Enterprise Associates
- MPM Capital
Reported by fiercebiotech.comSEC filing: $10M sold, first sale Mar 2010

Founders and team

From Rhythm Pharmaceuticals's own website and the SEC filings it signed: 8 on the team.

Keith GottesdienerMr. Gottesdiener is the Chief Executive Officer of the Issuer.i
Jennifer LeeExecutive Vice President, Head of North America
Jim FlahertySenior Vice President and General Counsel
Yann MazabraudExecutive Vice President, Head of International
Bart T. HendersonMr. Henderson is the President and Treasurer of the Issuer.i
Alicia FiscusChief Regulatory Officer
Hunter SmithChief Financial Officer
Joe ShulmanChief Technical Officer